Dynamic Shifts in ER–Plasma Membrane Junctions Signaling Define Pro‐Metastatic N‐Glycosylation and Predict Prostate Cancer Progression
Source abstract
Abstract
ABSTRACT Prostate cancer (PCa) is the second most common and a leading cause of cancer‐related deaths among men. Current screening methods lack precision in distinguishing aggressive cases, emphasizing a need for tissue‐based biomarkers. Although Golgi disorganization, ER stress, and elevated high‐mannose (Man) glycoproteins (e.g., Integrin α v , key metastatic player) are recognized features of metastatic prostate tumors, their interrelationships remain unexplored. It is observed that the growth of primary prostate tumors is linked to an increase in endoplasmic reticulum (ER)–plasma membrane (PM) junctions signaling, mediated by STIM1 and ORP5. However, transition to lymph node and tissue metastasis is associated with their downregulation, loss of ER–PM communications, significant Golgi dispersal, and rapid conversion of high‐Man glycans in the Golgi to atypical MGAT5‐modified sugars that facilitate Integrin α v clustering at the PM via Galectin‐3 binding. Golgi dispersal is associated with increased organelle volume and surface area to accommodate heightened trafficking and processing. These findings position STIM1 and ORP5 as biomarkers of aggressive PCa and show that high‐Man enrichment is not due to defective maturation but reflects a glycan pool that cancer cells actively utilize, suggesting that the concept of ER stress response in PCa should be redefined to include Golgi reorganization and altered ER–PM junctions.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Endoplasmic Reticulum Stress and Disease · Cellular transport and secretion · Clusterin in disease pathology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry and Molecular Biology University of Nebraska Medical Center Omaha Nebraska USA
The Fred and Pamela Buffett Cancer Center Omaha Nebraska USA
Department of Pathology, Microbiology, and Immunology University of Nebraska Medical Center Omaha Nebraska USA
Division of Urologic Surgery Department of Surgery University of Nebraska Medical Center Omaha Nebraska USA
The Nebraska Center for Integrated Biomolecular Communication University of Nebraska‐Lincoln Lincoln Nebraska USA
Department of Chemistry University of Nebraska‐Lincoln Lincoln Nebraska USA
Center for Biotechnology University of Nebraska‐Lincoln Lincoln Nebraska USA
Department of Statistics University of Nebraska‐Lincoln Lincoln Nebraska USA
Department of Urology University of Washington Seattle Washington USA
CardiOmics Program Center For Heart and Vascular Research and Department of Cellular and Integrative Physiology University of Nebraska Medical Center Omaha Nebraska USA
Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska USA
Funding
U.S. Department of Veterans Affairs · National Institute on Alcohol Abuse and Alcoholism · National Institutes of Health
References (100+)
Show source-provided references
1. 10.3322/caac.2187110.3322/caac.21871 ↗
2. 10.3322/caac.2170810.3322/caac.21708 ↗
3. 10.1056/NEJMoa081069610.1056/NEJMoa0810696 ↗
4. 10.1056/NEJMoa111313510.1056/NEJMoa1113135 ↗
5. 10.1002/cncr.3154910.1002/cncr.31549 ↗
6. 10.6004/jnccn.2019.002310.6004/jnccn.2019.0023 ↗
7. Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study
8. 10.3390/clinpract1402003910.3390/clinpract14020039 ↗
9. 10.1016/j.ijrobp.2022.06.10110.1016/j.ijrobp.2022.06.101 ↗
10. 10.1097/JU.000000000000275710.1097/JU.0000000000002757 ↗
11. 10.21767/2471-8084.10000610.21767/2471-8084.100006 ↗
12. The Impact of Alcohol on Pro‐Metastatic N‐Glycosylation in Prostate Cancer
13. 10.1074/jbc.M30067620010.1074/jbc.M300676200 ↗
14. 10.2164/jandrol.111.01388810.2164/jandrol.111.013888 ↗
15. 10.1158/1541-7786.MCR-14-0291-T10.1158/1541-7786.MCR-14-0291-T ↗
16. 10.1158/1541-7786.MCR-18-057710.1158/1541-7786.MCR-18-0577 ↗
17. 10.1186/s13046-021-02066-710.1186/s13046-021-02066-7 ↗
18. 10.1158/1541-7786.MCR-23-010810.1158/1541-7786.MCR-23-0108 ↗
19. 10.3389/fonc.2014.0013810.3389/fonc.2014.00138 ↗
20. 10.1016/j.apsb.2023.10.01410.1016/j.apsb.2023.10.014 ↗
21. 10.1158/1541-7786.MCR-20-096710.1158/1541-7786.MCR-20-0967 ↗
22. 10.1038/s41698-023-00363-210.1038/s41698-023-00363-2 ↗
23. 10.1002/anie.20151149110.1002/anie.201511491 ↗
24. 10.1002/pmic.20190001010.1002/pmic.201900010 ↗
25. 10.3389/fonc.2021.80917010.3389/fonc.2021.809170 ↗
26. 10.1074/mcp.RA120.00232010.1074/mcp.RA120.002320 ↗
27. 10.1155/2008/51531810.1155/2008/515318 ↗
28. 10.1021/pr060664t10.1021/pr060664t ↗
29. 10.5355/JAST.2011.A12910.5355/JAST.2011.A129 ↗
30. 10.1126/science.126041910.1126/science.1260419 ↗
31. 10.1074/mcp.M115.04792810.1074/mcp.M115.047928 ↗
32. 10.3389/fcell.2021.62770010.3389/fcell.2021.627700 ↗
33. 10.3390/cancers1205107110.3390/cancers12051071 ↗
34. 10.1016/j.ceca.2018.11.00910.1016/j.ceca.2018.11.009 ↗
35. 10.1016/j.cub.2005.05.05510.1016/j.cub.2005.05.055 ↗
36. 10.3389/fcell.2020.62221510.3389/fcell.2020.622215 ↗
37. 10.3389/fcell.2024.139909210.3389/fcell.2024.1399092 ↗
38. 10.3892/or.2017.596110.3892/or.2017.5961 ↗
39. 10.1038/srep1175410.1038/srep11754 ↗
40. 10.1038/cddis.2010.5210.1038/cddis.2010.52 ↗
41. 10.1042/BJ2012186410.1042/BJ20121864 ↗
42. 10.7150/thno.4402510.7150/thno.44025 ↗
43. 10.1126/scisignal.ads655010.1126/scisignal.ads6550 ↗
44. 10.1083/jcb.20160604710.1083/jcb.201606047 ↗
45. 10.1158/0008-5472.CAN-17-154410.1158/0008-5472.CAN-17-1544 ↗
46. 10.1111/jcmm.1739510.1111/jcmm.17395 ↗
47. 10.1007/s00018-018-2795-y10.1007/s00018-018-2795-y ↗
48. 10.3892/ijo.2015.300010.3892/ijo.2015.3000 ↗
49. 10.1074/jbc.M114.61018810.1074/jbc.M114.610188 ↗
50. 10.1007/s12192-023-01357-610.1007/s12192-023-01357-6 ↗
51. Uhlén M. · 2025
52. Expression of OSBPL5 in cancer. The Human Protein Atlas Science for Life Laboratory / Knut & Alice Wallenberg Foundation (2025) https://www.proteinatlas.org/ENSG00000021762‐OSBPL5/cancer.
53. 10.1083/jcb.20100414210.1083/jcb.201004142 ↗
54. 10.1152/ajpheart.00075.201410.1152/ajpheart.00075.2014 ↗
55. 10.1074/jbc.M60500220010.1074/jbc.M605002200 ↗
56. 10.1515/bmc-2022-001210.1515/bmc-2022-0012 ↗
57. 10.1073/pnas.230141012010.1073/pnas.2301410120 ↗
58. 10.1016/j.celrep.2023.11354010.1016/j.celrep.2023.113540 ↗
59. 10.1002/ijc.291021030510.1002/ijc.2910210305 ↗
60. GOK: A Gene at 11p15 Involved in Rhabdomyosarcoma and Rhabdoid Tumor Development
61. 10.1016/S0167-4838(02)00211-X10.1016/S0167-4838(02)00211-X ↗
62. 10.1186/s40425-019-0591-310.1186/s40425-019-0591-3 ↗
63. 10.26508/lsa.20190043110.26508/lsa.201900431 ↗
64. 10.1038/s42003-022-03968-810.1038/s42003-022-03968-8 ↗
65. 10.1371/journal.pone.024563810.1371/journal.pone.0245638 ↗
66. 10.1200/JCO.2008.20.466910.1200/JCO.2008.20.4669 ↗
67. 10.3389/fonc.2019.0064610.3389/fonc.2019.00646 ↗
68. 10.1038/srep3391810.1038/srep33918 ↗
69. 10.1016/j.urolonc.2024.01.03210.1016/j.urolonc.2024.01.032 ↗
70. 10.1016/j.cell.2013.05.05410.1016/j.cell.2013.05.054 ↗
71. 10.1073/pnas.150319111210.1073/pnas.1503191112 ↗
72. 10.1113/JP27114210.1113/JP271142 ↗
73. 10.1111/ejn.1665710.1111/ejn.16657 ↗
74. 10.1083/jcb.20190516210.1083/jcb.201905162 ↗
75. 10.1038/ncb286510.1038/ncb2865 ↗
76. 10.1038/s41375-021-01234-010.1038/s41375-021-01234-0 ↗
77. 10.7554/eLife.8357810.7554/eLife.83578 ↗
78. 10.1038/s41585-022-00649-310.1038/s41585-022-00649-3 ↗
79. 10.1002/cncr.2442310.1002/cncr.24423 ↗
80. 10.1158/1940-6207.CAPR-18-005710.1158/1940-6207.CAPR-18-0057 ↗
81. 10.1007/s10552-016-0778-610.1007/s10552-016-0778-6 ↗
82. 10.1002/ijc.2787710.1002/ijc.27877 ↗
83. 10.1016/j.eururo.2014.01.03710.1016/j.eururo.2014.01.037 ↗
84. 10.1002/ijc.2842310.1002/ijc.28423 ↗
85. 10.1002/ijc.3130710.1002/ijc.31307 ↗
86. 10.1093/aje/kwr21010.1093/aje/kwr210 ↗
87. 10.3390/biom1203037510.3390/biom12030375 ↗
88. 10.1152/ajpgi.00183.201510.1152/ajpgi.00183.2015 ↗
89. 10.1152/ajpgi.00109.202010.1152/ajpgi.00109.2020 ↗
90. 10.1111/iju.1313710.1111/iju.13137 ↗
91. 10.1158/0008-5472.CAN-09-271910.1158/0008-5472.CAN-09-2719 ↗
92. 10.1074/jbc.M115.71283610.1074/jbc.M115.712836 ↗
93. 10.1073/pnas.92.19.875410.1073/pnas.92.19.8754 ↗
94. 10.3389/fcell.2021.80648210.3389/fcell.2021.806482 ↗
95. Lectin‐Enzyme Assay as a Method of Estimation of Immunoglobulins' glycosylation
96. 10.1038/bjc.2013.69010.1038/bjc.2013.690 ↗
97. 10.1038/s41391-017-0016-710.1038/s41391-017-0016-7 ↗
98. 10.1016/S0021-9258(18)33465-310.1016/S0021-9258(18)33465-3 ↗
99. 10.1093/glycob/cwu01910.1093/glycob/cwu019 ↗
100. 10.1016/j.cell.2013.05.02610.1016/j.cell.2013.05.026 ↗